Forty Seven Inc
acquired by GileadPalo Alto, US · Founded 2014 · 14,911 employees on LinkedIn · 3 known investors
Acquired by Gilead Sciences March 2020 · terms undisclosed
Forty Seven Inc was a clinical-stage immuno-oncology company developing antibody therapies targeting CD47, a "don't eat me" signal exploited by cancer cells, with lead candidate magrolimab. Acquired by Gilead Sciences in 2020.
Founders & leadership
CS
Christopher SchaepeNamed on SEC filing
DH
Dennis HennerNamed on SEC filing
RM
Ravindra MajetiNamed on SEC filing
EJ
Eric JensenNamed on SEC filing
IW
Irving WeissmanNamed on SEC filing
Board
JB
Jeffrey BirdBoard director
JM
Jonathan MacQuittyBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$109.1M disclosed across 2 rounds · 2015–2017
▶$75MraisedOct 2017 · 32 investors · PharmaceuticalsRule 506(b)
▶$75MraisedOct 2017 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ravindra MajetiDirector
- Mark A. McCamishExecutive Officer, Director
- Chris SchaepeDirector
- Irving WeissmanDirector
- Dennis HennerDirector
- Jeffrey BirdDirector
- Jonathan MacQuittyDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$34.1MraisedMar 2016 · 32 investors · PharmaceuticalsRule 506(b)
▶$34.1MraisedMar 2016 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher SchaepeDirector
- Jeffrey BirdDirector
- Dennis HennerDirector
- Ravindra MajetiDirector
- Eric JensenExecutive Officer
- Irving WeissmanDirector
- Jonathan MacQuittyExecutive Officer, Director
- Offering amount
- $74.8M
- Amount sold
- $34.1M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Forty Seven Inc do?
- Forty Seven Inc was a clinical-stage immuno-oncology company developing antibody therapies targeting CD47, a "don't eat me" signal exploited by cancer cells, with lead candidate magrolimab. Acquired by Gilead Sciences in 2020.
- Who are Forty Seven Inc's investors?
- Forty Seven Inc's investors include Bluebird Ventures, Lightspeed Venture Partners, Sofinnova Ventures.
- How much funding has Forty Seven Inc raised?
- Forty Seven Inc has disclosed $109.1M raised across 2 rounds.
- Who acquired Forty Seven Inc?
- Forty Seven Inc was acquired by Gilead.
- Where is Forty Seven Inc headquartered?
- Forty Seven Inc is headquartered in Palo Alto, US.